Navigation Links
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Date:3/5/2008

om the Phase III FIT study. We are currently testing this clinically important potential of Zevalin consolidation in our ongoing phase III post-marketing commitment trial."

Details of the Study

The phase II trial, reported by P.L. Zinzani et. al. from the Institute of Hematology and Medical Oncology at the University of Bologna and the Department of Nuclear Medicine at S. Orsola-Malpighi Hospital in Bologna Italy, was a prospective, single-arm, open-label, non-randomized study combining CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus Zevalin, which was conducted to evaluate the efficacy and safety of this regimen as first-line therapy in elderly (60 years of age or older) DLBCL patients. The ORR was 100 percent, including 95 percent CR and 5 percent partial remission (PR). Four (80 percent) of the five patients who achieved less than a CR with CHOP improved their remission status after receiving Zevalin. With a median follow-up of 15 months, the 2-year progression-free survival was estimated to be 75 percent, with a 2-year overall survival of 95 percent. The toxicity associated with Zevalin included severe (grade 3 or 4) hematologic toxicity in 12 of 20 patients; the most common severe side effects were neutropenia (12 patients) and thrombocytopenia (7 patients). Transfusions of platelets were given to one patient.

About Zevalin(R)

Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patient
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
4. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
5. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
8. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
11. Anthrax vaccine produces immunity with nanoparticles, not needles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... --  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) ... 35 th Annual Health Care Conference on Tuesday, March ... .  Lexicon management will provide an overview of Lexicon,s ... the presentation will be available through Lexicon,s website at ... available at www.lexpharma.com until April 3, 2015. ...
(Date:2/26/2015)... SAN FRANCISCO, Calif. , Feb. 26, 2015 /PRNewswire/ ... the treatment of cancer, today announced that Sean ... a corporate overview at the upcoming Cowen and Company ... Boston . Dr. McCarthy,s presentation will take ... About CytomX Therapeutics CytomX Therapeutics develops ...
(Date:2/26/2015)... Caris Life Sciences® today announced the ... Cancers Symposium in Orlando, Fla. ... profiling. Both studies utilized Caris Molecular Intelligence™, the ... biomarkers that shed light on potential treatment strategies ... cancer (SCBC). In one study, ...
(Date:2/25/2015)... Technologies Inc. (TSX-V: RTI) (the "Corporation") announced today that ... quarter of its fiscal year ended March 31, 2015. ... the CEO & CFO certifications for the three and ... on www.SEDAR.com . CFO ... pleased to announce the appointment of Prakash Hariharhan as ...
Breaking Biology Technology:Lexicon To Present At The Cowen 35th Annual Health Care Conference 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 3Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 4Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 5Radient Technologies Inc. Releases Third Quarter Results and Appoints New Interim CFO 2
... is Japan. In this column, I have covered different aspects ... 3/28/05). I had the good fortune to return to Japan ... a three-year hiatus. , ,My last visit there was ... sister city relationship, which had started in Chicago and culminated ...
... Wis. - GE Healthcare , the $15 billion ... U.S. Food and Drug Administration clearance for its heart-imaging ... 70 percent per scan. , ,The technology is based on ... multiple X-ray images together to create a three-dimensional image of ...
... Wis. - Cyber threats are becoming more sophisticated ... companies aren't acting on the threats, a panel of ... on the state of information security during the annual ... technology executives continued to emphasize the necessary balance between ...
Cached Biology Technology:Japan on the rebound: Implications for Midwest 2Japan on the rebound: Implications for Midwest 3Japan on the rebound: Implications for Midwest 4Japan on the rebound: Implications for Midwest 5Japan on the rebound: Implications for Midwest 6Japan on the rebound: Implications for Midwest 7Japan on the rebound: Implications for Midwest 8Japan on the rebound: Implications for Midwest 9FDA approves GE's heart-imaging technology 2Companies still neglect network security 2
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... FindBiometrics, the leading source of biometrics industry news, interviews and ... "When we launched FindBiometrics 12 years ago the ... founder and CEO of FindBiometrics. "Now it,s maturing very quickly. ... players on a very broad scale.  We are known for ...
(Date:1/22/2015)... , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... market, reports on the recent success of the Wocket™ smart wallet at ... Wocket smart wallet was named as one of the "11 Hot Products ... Best Products Launched At CES So Far" by Newseveryday.com and "The top ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... is available in German . ... In the wild Arabidopsis thaliana uses the same ... its size in half as found in semi-dwarf varieties of rice and ... various plant species apparently fall back on the same genes in their ...
... abdominal surgery may paradoxically prolong a patient,s suffering, doubling ... to recover from the surgical pain, according to researchers ... team from CU-Boulder,s Department of Psychology and Neuroscienceled by ... Galer, a professional research assistantwas able to identify the ...
... solar panels, wringing every drop of energy from as ... has sent chemistry, materials science and electronic engineering researchers ... photovoltaic devices, but existing techniques are now running up ... Now, researchers from the University of Pennsylvania ...
Cached Biology News:The secret of short stems 2The secret of short stems 3Using morphine after abdominal surgery may prolong pain, CU-Boulder researchers find 2Penn and Drexel team demonstrates new paradigm for solar cell construction 2Penn and Drexel team demonstrates new paradigm for solar cell construction 3Penn and Drexel team demonstrates new paradigm for solar cell construction 4Penn and Drexel team demonstrates new paradigm for solar cell construction 5
... Plant Leaf DNA Purification Kit is designed for ... leaf tissue. The protocol can be completed in ... up to obtain larger amounts of DNA. The ... restriction digestion, and Southern blotting. The MasterPure Kit ...
Caspase Activity Detector, SR-VAD-FMK Kit , 100 tests Consult technical datasheet for details....
HistoScan AP Universal Goat Kit...
...
Biology Products: